Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells

Acta Neurochirurgica

Volumn 146, Issue 7, 2004, Pages 721-729

  Jeremias, Irmela ^a   Steiner, H H ^b   Benner, A ^c   Debatin, K M ^d   Herold Mende, C ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Betulinic acid; Ceramide; Glioblastoma multiforme WHO IV; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; BETULIC ACID; CARMUSTINE; CERAMIDE; CISPLATIN; CYTOTOXIC AGENT; DNA; DOXORUBICIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINCRISTINE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CELL DEATH; CLINICAL ARTICLE; CYTOTOXICITY; FEMALE; GAMMA IRRADIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; NERVE CELL NECROSIS; NEUROSURGERY; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR GROWTH; MULTIDRUG RESISTANCE; NOTE;

EID: 3042848683     PISSN: 00016268     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00701-004-0286-4     Document Type: Article

References (23)

1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 4: 155-162
2. Cox RD (1972) Regression models and life-tables. J Royal Stat Soc Series B 34: 187-220
3. Fenner MH, Possinger K (2002) Chemotherapy for breast cancer brain metastases. Onkologie 25: 474-479
4. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nunez G, Krammer PH, Peter ME, Debatin KM (1997) Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57: 4956-4964
5. Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808-815
6. Herold-Mende C, Steiner HH, Andl T, Riede D, Buttler A, Reisser C, Fusenig NE, Mueller MM (1999) Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest 79: 1573-1582
7. Jendrossek V, Belka C, Bamberg M (2003) Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opin Investig Drugs 12: 1899-1924
8. Jeremias I, Herr I, Boehler T, Debatin KM (1998) TRAIL/Apo-2-Ligand induced apoptosis in T-cells. Eur J Immunol 28: 143-152
9. Kelley SK, Harris L, Xie D, DeForge L, Totpal K, Bussiere J, Fox JA (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299: 31-38
10. Kolesnick R (2002) The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 110: 3-8
11. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 139: 271-279
12. Paul C, Liliemark J, Tidefelt U, Gahrton G, Peterson C (1989) Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther Drug Monit 11: 140-148
13. Rahmani R, Zhou XJ (1993) Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 17: 269-281
14. Riva C, Lavieille JP, Schmerber S, Cuisnie O, Reyt E (2000) Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. Int J Oncol 17: 543-549
15. Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J, Ashkenazi A, Weller M (1999) Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 265: 479-483
16. Sakuma S, Sawamura Y, Tada M, Aida T, Abe H, Suzuki K, Taniguchi N (1993) Responses of human glioblastoma cells to human natural tumor necrosis factor-alpha: susceptibility, mechanism of resistance and cytokine production studies. J Neurooncol 15: 197-208
17. Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P (1999) Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46: 183-188
18. Skalski V, Rivas J, Panasci L, McQuillan A, Feindel W (1988) The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man. Cancer Chemother Pharmacol 22: 137-140
19. Steiner HH, Herold-Mende C, Bonsanto M, Geletneky K, Kunze S (1998) Zur Prognose von Hirntumoren: Epidermiologie, Überlebenszeit und klinischer Verlauf. Versicherungsmedizin 5: 173-178
20. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163
21. Wirtz CR, Knauth M, Staubert A, Bonsanto M, Sartor K, Kunze S, Tronnier V (2000) Clinical evaluation and follow-up results for intraoperative magnetic resonance imaging in Neurosurgery. Neurosurgery 46: 1112-1121
22. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H (1999) Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 125: 481-486
23. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C, Formelli F (2002) Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 175: 17-25